which glp 1 drugs are approved for obesity The GLP-1 revolution: What UAB researchers discovering about how these work Use of diabetes and anti-obesity

After 72 weeks: Participants taking 6 mg of orforglipron lost an average of 7.5% of their body weight (equivalent to 9 mg of Foundayo) Participants taking 12 mg or 37 mg of orforglipron lost an average of 8.4% and 11.2%, respectively (equivalent to 14.5 mg or 17.2 mg of Foundayo, respectively) Side effects and risks of GLP-1s The most common side effects from these medicines are mild gastrointestinal (GI) issues, such as: Vomiting Diarrhea Abdominal pain Rare but serious side effects of GLP-1s may include: Pancreatitis, or inflammation of the pancreas Gallbladder disease (including gallstones or gallbladder inflammation) Low blood sugar ( hypoglycemia ), particularly in people who also take insulin or certain pills for diabetes Severe allergic reactions Severe gastrointestinal reactions, which may lead to dehydration and related kidney problems Diabetic retinopathy complications in people with this eye disease Risk of pulmonary aspiration ( stomach contents entering the lungs) during surgery in people undergoing deep sedation or anesthesia GLP-1s also carry a boxed warning because they caused thyroid C-cell tumors in studies of rats

Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo

Glucagon-like peptide-1 receptor agonists (herein GLP-1s) have emerged as agents for weight loss and obesity treatment

NAC is also a common prescription to be used with a nebulizer (the drug is acetylcysteine) for those with COPD or respiratory issues

Ozempic (semaglutide), a GLP-1 receptor agonist, is a prescription medication most commonly used to manage blood sugar levels in people with Type 2 diabetes